Production (Stage)
Ocular Therapeutix, Inc.
OCUL
$9.02
$0.566.62%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -192.71M | -193.51M | -174.34M | -138.36M | -115.27M |
| Total Depreciation and Amortization | 3.85M | 3.79M | 3.79M | 3.72M | 3.42M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 35.10M | 65.27M | 70.48M | 55.97M | 45.62M |
| Change in Net Operating Assets | 8.31M | -10.23M | -17.64M | -10.21M | -17.92M |
| Cash from Operations | -145.46M | -134.68M | -117.70M | -88.88M | -84.15M |
| Capital Expenditure | -2.97M | -1.29M | -1.55M | -1.72M | -2.96M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -2.97M | -1.29M | -1.55M | -1.72M | -2.96M |
| Total Debt Issued | -- | -- | 0.00 | 82.47M | 82.47M |
| Total Debt Repaid | -- | -- | 0.00 | -26.13M | -26.13M |
| Issuance of Common Stock | 15.07M | 332.11M | 435.77M | 432.36M | 439.81M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | -5.18M | -5.18M |
| Cash from Financing | 15.07M | 332.11M | 435.77M | 483.52M | 490.97M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -133.36M | 196.15M | 316.52M | 392.93M | 403.86M |